摘要
目的:探讨18F-FDG PET/CT对弥漫大B细胞淋巴瘤(diffuse B-cell large lymphoma,DLBCL)临床分期及评价化疗中期治疗反应的价值。方法:29例初诊的DLBCL化疗前和化疗中期均行18F-FDG PET/CT检查,根据肿瘤对化疗的反应将病例分为无反应组、部分反应组及完全反应组,采用χ2检验和Fisher确切概率法比较3组患者的完全缓解率。结果:18F-FDG PET/CT改变了10.3%(3/29)患者的临床分期。无反应组、部分反应组及完全反应组的临床完全缓解率分别为16.7%(1/6)、69.2%(9/13)和80.0%(8/10),3组间差异有统计学意义(χ2=7.033,P=0.030)。完全反应组、部分反应组的完全缓解率明显高于无反应组(χ2=4.310,P=0.038;χ2=5.730,P=0.017)。结论:18F-FDG PET/CT显像有助于临床分期;化疗中期18F-FDG PET/CT显像有助于预测化疗疗效。
Objective：To explore the value of 18F-FDG PET/CT on clinical staging and assessment of chemotherapy response in patients with diffuse large B-cell lymphoma（DLBCL）. Methods：18F-FDG PET/CT was performed before and after 3 or 4 cycles of chemotherapy in 29 patients with DLBCL. The patients were divided into three the groups：no response group,the partial response group and the complete response group. We compared the complete remission rate（CR） between the three groups. χ2 test and Fisher exact test were performed with SPSS 17.0. Results：The stage of disease was changed in three patients（10.3%,3/29）on the basis of pre-treatment 18F-FDG PET/CT. CR rates of the no response group,the partial response group and the complete response group were 16.7%,69.2% and 80.0%,respectively（χ2 = 7.033,P = 0.030）. CR rates of the complete response group and the partial response group were significantly higher than those of the no response group（χ2 = 4.310,P = 0.038;χ2 = 5.730,P = 0.017）. Conclusion：18F-FDG PET/CT may be useful for clinical staging and assessment of chemotherapy response of middle stage in DLBCL.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2014年第1期94-98,共5页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金青年基金(81202032)
